Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of ...

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients ...
Targeted Oncology

AVC-203 Achieves Trial Approval from FDA, EMA for R/R B-Cell Lymphoma

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...
The Scientist

A Red Blood Cell Protein Turns Dendritic Cells Tolerant

Erythropoietin, the protein that drives red blood cell formation, also induces tolerance in dendritic cells, leading to the ...

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Ly…

B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of ...
Mirage News

Scientists Uncover T Cell Receptor Structure, End Debate

Ryan Notti (left) and Thomas Walz (right) discovered new characteristics of a T cell receptor that are essential to a variety ...

Imviva Biotech Presents Validating Data for CAR-T Cell Therapies CTD402 and CTA311 in Five Presentations at the 67th American Society of Hematology Annual Meeting

Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
FierceBiotech

Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial

Cabaletta Bio’s CAR-T cell therapy has eliminated the overreactive B cells of two patients with an autoimmune disease without preconditioning chemotherapy, pleasing investors and analysts while ...